An observational study in Heart Failure, Circulatory Disorders Postprocedural Complication and Cardiomyopathy, Congestive, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.
Sponsored by University of Colorado, Denver · Observational
Among 21 studies in Heart Failure by University of Colorado, Denver — 2 open to participants now, 8 under way, none of them phase 3. Heart Failure · University of Colorado, Denver.
Among the 21 studies in Heart Failure by University of Colorado, Denver, this one is one of 2 that started in 2018, is one of 5 observational ones, and was the 11th registered.
6,332 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →2 of the 21 studies in Heart Failure by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 18+
University of Colorado, Denver
Ages 18–89
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 200 across 1,983 observational studies indexed under Heart Failure.
Median enrollment 85 across the 16 interventional studies, 53 across the 5 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
2 of the studies in Heart Failure by University of Colorado, Denver that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852509University of Colorado, DenverDigital Health Physical Activity Program for Older Family Care Partners of Patents With Heart Failure | 2027-03-31 |
| NCT06097481University of Colorado, DenverNarrative Intervention for Chronic Illness- Heart Failure Trial (NICI-HF) | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Heart Failure by University of Colorado, Denver, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall objective of this pilot analysis is to characterize the hemodynamic changes that occur during implantation of a left ventricular assist device (LVAD) in patients with advanced heart failure - specifically, how right ventricular function is compromised as a result of LVAD implantation.
Patients with advanced HF who are scheduled to undergo LVAD implantation with either the Heartmate 2, Heartmate 3 (Abbott, Abbott Park, IL) or HVAD (Medtronic, Minneapolis, MD) LVADs
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with pre-existing right ventricular (RV) dysfunction/failure, defined as:
Hemodynamic evidence of RV dysfunction with:
Change in Cardiovascular hemodynamics (invasive and noninvasive)
Cardiovascular hemodynamics will be measured both invasively and noninvasively as standard-of-care during LVAD implantation in the Operating Room (OR), and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Heart Rate (HR)
Changes in HR will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Blood Pressure (BP)
Changes in BP will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Right Atrial (RA) pressure
Changes in RA pressure will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in pulmonary pressure
Pulmonary pressure changes will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Cardiac output
Cardiac output changes will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Right ventricular function
Right ventricular function will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Change in Brain blood flow
Brain blood flow will be evaluated during LVAD implantation in the OR, and immediately afterwards in the CT-ICU unit prior to discharge.
Time frame: During LVAD implant and for 12-24 hours during ICU admission
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2018 to primary completion in Jun 2020, 20 months.
Of 794 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 99. This study's 20 months is below that.
Counting every sponsor, half of 976 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →